Natalja Genina

Dr. Natalja Genina


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NGNatalja Genina
Natalja Genina
JHJenny Holländer
Jenny Holländer
HJHarri Jukarainen
Harri Jukarainen
EMErmei Mäkilä
Ermei Mäkilä
JSJarno Salonen
Jarno Salonen
NSNiklas Sandler
Niklas Sandler

1 September 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JHJenny Holländer
Jenny Holländer
NGNatalja Genina
Natalja Genina
HJHarri Jukarainen
Harri Jukarainen
MKMohammad Khajeheian
Mohammad Khajeheian
ARAri Rosling
Ari Rosling
NSNiklas Sandler
Niklas Sandler

1 December 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
NGNatalja Genina
Natalja Genina
JBJohan Bøtker
Johan Bøtker
SCStefano Colombo
Stefano Colombo
NHNecati Harmankaya
Necati Harmankaya
JRJukka Rantanen
Jukka Rantanen
ABAdam Bohr
Adam Bohr

1 January 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NSNiklas Sandler
Niklas Sandler
ISIda Salmela
Ida Salmela
AFAdyary Fallarero
Adyary Fallarero
ARAri Rosling
Ari Rosling
MKMohammad Khajeheian
Mohammad Khajeheian
PVPia Vuorela
Pia Vuorela

1 September 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
DRDhara Raijada
Dhara Raijada
Katarzyna WacKatarzyna Wac
Katarzyna Wac
EGEmanuel Greisen
Emanuel Greisen
JRJukka Rantanen
Jukka Rantanen
NGNatalja Genina
Natalja Genina
Personalized drug delivery systems (PDDS), implying the patient-tailored dose, dosage form, frequency of administration and drug release kinetics, and digital health platforms for diagnosis and treatment monitoring, patient adherence, and traceability of drug products, are emerging scientific areas. Both fields are advancing at a fast pace. However, despite the strong complementary nature of these disciplines, there are only a few successful examples of merging these areas. Therefore, it is important and timely to combine PDDS with an increasing number of high-end digital health solutions to create an interactive feedback loop between the actual needs of each patient and the drug products. This review provides an overview of advanced design solutions for new products such as interactive personalized treatment that would interconnect the pharmaceutical and digital worlds. Furthermore, we discuss the recent advancements in the pharmaceutical supply chain (PSC) management and related limitations of the current mass production model. We summarize the current state of the art and envision future directions and potential development areas.

1 October 2012 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NGNatalja Genina
Natalja Genina
DFDaniela Fors
Daniela Fors
HVHossein Vakili
Hossein Vakili
PIPetri Ihalainen
Petri Ihalainen
LPLeena Pohjala
Leena Pohjala
NSNiklas Sandler
Niklas Sandler